A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
for Duchenne Muscular Dystrophy
22 locations incl. Little Rock
Sponsor: Sarepta Therapeutics, Inc.
Sex: Male·Age: All ages
Code: NCT05967351·Phase 3·Enrolling By Invitation